Gilead Sciences Inc. ($GILD) Stock Forecast: Up 5.1% Today

What is Gilead Sciences Inc.?

Gilead Sciences (GILD) is a biopharmaceutical company known for its HIV prevention therapies and innovative drug launches. The overall market sentiment for GILD has been positive due to strong earnings performance.

Why is Gilead Sciences Inc. going up?

GILD stock is up 5.1% on Feb 11, 2026 19:26

• Gilead Sciences reported upbeat Q4 earnings, beating estimates and driven by growth in HIV prevention therapies and the launch of Yeztugo, leading to a bullish market movement.
• Despite weaker-than-expected fiscal 2026 guidance, analysts raised price targets and reiterated positive ratings, indicating confidence in the company's future prospects.
• Institutional investors adjusting their stakes and new acquisitions in GILD suggest continued interest and support in the company's growth trajectory.
• The market reaction to Gilead's earnings beat and dividend increase showcases investor optimism, despite concerns about future guidance and performance in non-HIV segments.

GILD Price Chart

GILD Technical Analysis

GILD News

Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Gilead Sciences reported upbeat fourth-quarter earnings, beating consensus estimates for both EPS and revenue, driven by strong growth in its HIV prevention therapies and the launch of Yeztugo. Despite the strong quarterly results, the company issued weaker-than-expected fiscal 2026 guidance, causing its shares to fall in pre-market trading. Following the earnings announcement, several analysts, including Needham, Scotiabank, and Cantor Fitzgerald, reiterated their positive ratings and raised their price targets for Gilead.

https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50539905/gilead-analysts-boost-their-forecasts-after-upbeat-q4-earnings

Rhumbline Advisers Sells 15,602 Shares of Gilead Sciences, Inc. $GILD

Rhumbline Advisers reduced its stake in Gilead Sciences (NASDAQ:GILD) by 0.7% in the third quarter, selling 15,602 shares. Despite this, other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Invesco Ltd. increased their positions in the biopharmaceutical company. Gilead Sciences recently announced a dividend increase and reported earnings that beat analyst estimates, although its FY 2026 guidance was below consensus, leading to some negative market reaction.

https://www.marketbeat.com/instant-alerts/filing-rhumbline-advisers-sells-15602-shares-of-gilead-sciences-inc-gild-2026-02-11/

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52

Amgen Inc. (NASDAQ:AMGN) is set to increase its dividend to $2.52, resulting in a dividend yield similar to the industry average at 2.8%. The company's earnings are projected to cover future distributions, with the payout ratio estimated at 61%, indicating sustainability. While Amgen has a strong history of growing dividends, its earnings growth has been slow, which could limit future dividend increases.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-nasdaqamgn-is-increasing-its-dividend-to-252-1

Caprock Group LLC Invests $7.23 Million in Gilead Sciences, Inc. $GILD

Caprock Group LLC has acquired a new stake worth approximately $7.23 million in Gilead Sciences, Inc. The article also notes that other institutional investors have adjusted their holdings in Gilead, and provides analyst ratings, financial performance, and recent insider trading activities for the company. Gilead Sciences recently announced an increase in its quarterly dividend and reported Q4 earnings that surpassed analyst estimates, despite current-year guidance being below expectations.

https://www.marketbeat.com/instant-alerts/filing-caprock-group-llc-invests-723-million-in-gilead-sciences-inc-gild-2026-02-11/

Gilead Sciences exceeds Q4 2025 earnings and revenue forecasts

Gilead Sciences reported strong Q4 2025 results, with product sales of $7.9 billion and adjusted EPS of $1.86, both surpassing analyst expectations, primarily driven by its HIV portfolio. Despite the earnings beat, the stock experienced a post-market decline due to high expectations for the new HIV prevention drug Yeztugo and softness in non-HIV segments like cell therapy. Gilead issued 2026 guidance projecting product sales of $29.6-$30 billion and non-GAAP EPS of $8.45-$8.85, along with a raised quarterly dividend, signaling confidence in future cash flow.

https://mlq.ai/news/gilead-sciences-exceeds-q4-2025-earnings-and-revenue-forecasts/

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 6.0% Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Up 5.2% Today

Trimble Inc. ($TRMB) Stock Forecast: Down 5.1% Today

Cognizant Technology Solutions Corporation ($CTSH) Stock Forecast: Down 5.1% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 6.7% Today

Charles Schwab Corporation (The) ($SCHW) Stock Forecast: Down 5.1% Today

Robert Half Inc. ($RHI) Stock Forecast: Down 7.0% Today

Delta Air Lines Inc. ($DAL) Stock Forecast: Down 5.6% Today

Intercontinental Exchange Inc. ($ICE) Stock Forecast: Down 7.4% Today

Vornado Realty Trust ($VNO) Stock Forecast: Down 5.1% Today

Gilead Sciences Inc. Price History

22.00.2026 - GILD Stock was up 5.6%

• Gilead Sciences experienced a strong bullish movement today, with a 4.0% increase in stock price, reaching $129.11.
• The bullish trend can be attributed to positive news surrounding the cell therapy market dynamics, where Gilead Sciences is a key player, showcasing advancements in research, clinical applications, and strategic partnerships.
• Additionally, the positive forecast issued by Rothschild & Co Redburn, raising the price target for Gilead Sciences to $159, further fueled investor confidence in the company's growth prospects.
• The recent study by Arcellx indicating the efficacy of CAR T-cell therapy in treating multiple myeloma and the strong earnings performance of Gilead Sciences in the past quarter have also contributed to the bullish sentiment surrounding the stock.

09.03.2025 - GILD Stock was down 5.1%

• Gilead Sciences (GILD) exhibited bearish movement, closing at $112.39 with a +0.45% change from the previous close.
• The positive momentum surrounding Gilead Sciences amid market decline could be linked to internal developments within the company.
• Various factors such as tariff tensions, geopolitical events, and uncertainties related to the Fed may have influenced the overall market sentiment, potentially overshadowing Gilead's performance.
• Attention from investors may have shifted towards other companies like Amazon and Alphabet, affecting Gilead Sciences' performance and contributing to its bearish movement.

05.00.2026 - GILD Stock was down 1.9%

• Gilead Sciences Inc. (GILD) faced a bearish market movement possibly due to the news of Repare Therapeutics announcing Gilead's acquisition of RP-3467 for up to $30 million. This acquisition might have raised concerns among investors about the potential impact on Gilead's financials or strategic direction.
• The appointment of Sung Lee, a finance leader with experience in biopharmaceutical companies including Gilead Sciences, to Tango Therapeutics' Board of Directors might have diverted some attention and resources away from Gilead, leading to a negative sentiment in the market.
• The strategic shift towards oncology and diversified product offerings by another company could have also influenced investors to reevaluate Gilead's position in the competitive landscape, contributing to the bearish movement.
• The evaluation of Gilead Sciences Inc. as a potential investment, contrasting its stability with operational risks like patent cliffs and trial failures, might have prompted some investors to reposition their portfolios, impacting GILD's stock performance negatively.

17.09.2025 - GILD Stock was up 5.3%

• A Buy rating and raised price target for Gilead Sciences by Citigroup analyst boosted investor confidence in the stock.
• Positive sentiment from CNBC's "Final Trades" segment likely attracted more attention from traders, contributing to the bullish movement.
• Endorsement from industry experts and media coverage could have sparked increased buying interest, leading to the strong bullish movement in GILD stock today.

06.04.2025 - GILD Stock was down 5.1%

• GILD saw a downward trend today after disappointing first-quarter results, particularly in the oncology sector.
• Advice for investors to adopt a cautious approach indicates uncertainty about the stock in the near future.
• The market's response to the earnings shortfall underscores the significance of consistent performance in crucial business divisions, like oncology, to uphold investor trust in pharmaceutical firms like GILD.

08.07.2025 - GILD Stock was up 9.8%

• GILD stock had a strong uptrend today.
• Strategies to generate monthly dividend income from owning GILD shares before Q2 earnings are highlighted.
• The surge in the stock price may be linked to positive investor outlook on GILD's upcoming earnings and dividend potential.
• Favorable market sentiment towards income-generating stocks like GILD might have contributed to the stock's uptick.

08.07.2025 - GILD Stock was up 8.9%

• In the second quarter, Gilead Sciences posted strong financial results, exceeding expectations with an adjusted EPS of $2.01 and revenue of $7.08 billion. This robust performance likely drove the positive movement in the stock price.
• Sales of key products such as Biktarvy and Descovy showed notable increases of 9% and 35% respectively, demonstrating the company's ability to meet market demand effectively and boost revenue.
• Investors showed optimism before Gilead Sciences' Q2 earnings release, fueling the surge in the stock price as they looked to benefit from potential dividend income and the company's growth prospects.

10.03.2025 - GILD Stock was down 5.6%

• GILD had a strong bearish movement despite a slight increase in its stock price in the previous trading day.
• The conflicting reports of GILD ascending while the market falls may have caused confusion among investors, leading to profit-taking and a bearish trend.
• Investors might be concerned about Gilead Sciences falling behind the market, possibly due to competition in the biopharmaceutical sector or delays in drug development.
• The overall market sentiment and the specific news about GILD's performance could have contributed to the bearish movement of the stock today.

11.01.2026 - GILD Stock was up 5.1%

• Gilead Sciences reported upbeat Q4 earnings, beating estimates and driven by growth in HIV prevention therapies and the launch of Yeztugo, leading to a bullish market movement.
• Despite weaker-than-expected fiscal 2026 guidance, analysts raised price targets and reiterated positive ratings, indicating confidence in the company's future prospects.
• Institutional investors adjusting their stakes and new acquisitions in GILD suggest continued interest and support in the company's growth trajectory.
• The market reaction to Gilead's earnings beat and dividend increase showcases investor optimism, despite concerns about future guidance and performance in non-HIV segments.

12.01.2025 - GILD Stock was up 7.5%

• Gilead Sciences experienced a notable increase in its stock price due to the announcement of better-than-expected fourth-quarter financial results and optimistic FY25 adjusted EPS guidance.
• The market responded positively to Gilead's strategic collaborations, including the recent partnership with LEO Pharma involving significant upfront payments and potential milestones.
• Despite prevailing market pessimism and concerns from institutional investors about Gilead Sciences options trading, the company's robust performance and promising future outlook appear to have driven the stock upwards.

12.01.2025 - GILD Stock was up 7.1%

• Gilead Sciences experienced a strong bullish movement today following the release of its Q4 financial results and optimistic outlook for 2025.
• The company reported a 6% increase in Q4 revenue, surpassing analyst expectations, and raised its dividend, signaling financial strength and confidence in future performance.
• The market reacted positively to Gilead's announcement of launching Lenacapavir for HIV prevention, indicating potential growth opportunities in its product pipeline.
• Overall, Gilead's solid financial performance and strategic developments have instilled investor confidence, driving the stock price higher in today's trading session.

31.09.2025 - GILD Stock was down 0.4%

• The bearish movement in GILD stock today could be attributed to investors' uncertainty ahead of the Q3 earnings report, despite the company's strong performance in the HIV sector.
• The long-term outperformance of Gilead Sciences in the market over the past 20 years might not be enough to offset current concerns about challenges in its Cell Therapy business, leading to a sell-off.
• Investors may be cautious due to the potential impact of the FDA approvals and how they might translate into revenue, causing some to take profits or reevaluate their positions in GILD stock.